Tilray TLRY Stock Analysis & is TLRY stock a good investment

Wall Street: GLP-1 competitors’ pain is Eli Lilly’s gain

Eli Lilly’s stock continued its wild ride Wednesday after lackluster data from Amgen’s potential GLP-1 competitor further demonstrated tirzepatide’s advantage. On Wednesday, Lilly shares $LLY

February 9, 2024

Visceral fat found to contribute to Alzheimer’s disease development

Researchers have linked a specific type of body fat to the abnormal proteins in the brain that are hallmarks of Alzheimer’s disease up to 20

December 2, 2024

Verona Ohtuvayre set to transform US COPD exacerbator market

The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is tailored towards patients with moderate

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.